Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

A number of other research analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, January 21st. JonesTrading assumed coverage on Context Therapeutics in a research report on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target for the company. Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research note on Tuesday, March 24th. Finally, Guggenheim restated a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Context Therapeutics Stock Down 5.4%

Shares of NASDAQ CNTX opened at $2.45 on Friday. The firm has a 50-day simple moving average of $2.50 and a 200-day simple moving average of $1.65. The stock has a market capitalization of $225.11 million, a price-to-earnings ratio of -6.45 and a beta of 1.97. Context Therapeutics has a 52 week low of $0.49 and a 52 week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). As a group, equities research analysts expect that Context Therapeutics will post -0.51 EPS for the current year.

Institutional Trading of Context Therapeutics

Several hedge funds have recently made changes to their positions in the company. Blue Owl Capital Holdings LP increased its holdings in shares of Context Therapeutics by 0.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock worth $10,926,000 after buying an additional 25,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after acquiring an additional 134,449 shares during the last quarter. Millennium Management LLC purchased a new position in Context Therapeutics in the fourth quarter worth approximately $3,824,000. Marshall Wace LLP grew its position in Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock worth $3,812,000 after acquiring an additional 2,557,448 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock worth $747,000 after acquiring an additional 188,202 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.